Podcasts

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Brad Rovin, Professor of Nephrology and Medical Director of the Ohio State University Clinical Research Management Institute. Together, they discuss the use of belimumab to reduce prednisone doses and the development of the SLESIS-R score for determining the risk of severe infection in SLE.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Victoria Werth, Professor of Dermatology and Medicine, University of Pennsylvania and Philadelphia Veterans Administration Hospital. Together, they discuss the latest developments in CAR T-cell therapy, development of Smith-specific regulatory T cells, and cardiovascular risk factors.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Chris Edwards, Consultant Rheumatologist and Honorary Chair of Clinical Rheumatology University Hospital Southampton, UK. Together, they discuss the latest developments and perspectives in glucocorticoid tapering, TYK2 therapy in rheumatic disease, as well as SLE QoL and LLDAS.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Professor Maria Dall’Era, Professor of Medicine and Chief of the Division of Rheumatology at the University of California in San Francisco, USA. Together, they discuss latest developments and perspectives in RNase therapy and patient-reported outcome quality measures in SLE, as well as serological predictors of renal flares.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Vibeke Strand, Adjunct Clinical Professor of Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, California. Together, they discuss the latest developments and perspectives in telitacicept therapy, fatigue, and disease burden.

Lupus Forum Chair Ed Vital, from the University of Leeds, is joined by Dr Chi Chiu Mok, Chief of the Division of Rheumatology at Tuen Mun Hospital in Hong Kong. Together, they discuss the ability of obinutuzumab to preserve kidney function in patients with lupus nephritis, real-world data for telitacicept therapy, and the relationship between HCQ nonadherence and SLE disease flares.